| Serial Number | 86797424 |
| Word Mark | EPIIOS |
| Filing Date | Friday, October 23, 2015 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, June 16, 2023 |
| Registration Number | 5093926 |
| Registration Date | Tuesday, December 6, 2016 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 20, 2016 |
| Goods and Services | Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, psychotropics; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient |
| Goods and Services | Active chemical ingredients for use in the manufacture of anti-cancer drugs; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating human diseases of any kind; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for general industrial manufacturing; Chemical preparations, namely, silica based density centrifugation media, to be used in biochemical and clinical research; Chemicals for use in biotechnological product development; Chemicals for use in the biochemical and chemical industry; Chemicals, namely, buffer and standard solutions used in analytical chemistry; Industrial chemicals, namely, crosslinking coagents for thermoplastics; Reagents for use in scientific apparatus for chemical or biological analysis |
| Goods and Services | Advanced product research in the field of artificial intelligence; Chemical, biochemical, biological and bacteriological research and analysis; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Consulting services in the field of medical physics; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Laboratory research services relating to pharmaceuticals; Medical research services in the field of cancer; Pharmaceutical research and development; Pharmaceutical research services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products; Research and development of new products for others; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, June 16, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, June 16, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, June 16, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | EPIIOS THERAPEUTICS GMBH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | BERLIN 10115 DE |
| Party Name | EPIIOS THERAPEUTICS GMBH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | BERLIN 10115 DE |
| Party Name | EPIIOS THERAPEUTICS GMBH |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | BERLIN 10115 DE |
| Party Name | IC Discovery GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Berlin 10115 DE |
| Event Date | Event Description |
| Friday, June 16, 2023 | CANCELLED SEC. 8 (6-YR) |
| Monday, December 6, 2021 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Tuesday, December 6, 2016 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, September 20, 2016 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 20, 2016 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 31, 2016 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, August 24, 2016 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Thursday, August 18, 2016 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Thursday, August 11, 2016 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 10, 2016 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, August 10, 2016 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, August 10, 2016 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, August 10, 2016 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, July 28, 2016 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, July 28, 2016 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 21, 2016 | ASSIGNED TO LIE |
| Tuesday, July 19, 2016 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 16, 2016 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, February 16, 2016 | NON-FINAL ACTION E-MAILED |
| Tuesday, February 16, 2016 | NON-FINAL ACTION WRITTEN |
| Tuesday, February 16, 2016 | ASSIGNED TO EXAMINER |
| Wednesday, October 28, 2015 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 27, 2015 | NEW APPLICATION ENTERED |